CSL Behring turns to SinoPharm (again) for Chinese market expansion



CSL Behring, a wholly owned subsidiary of Australia-based CSL Ltd (ASX:CSL), announced the strategic partnership with China-based Sinopharm Group Co., Ltd, a subsidiary of state-owned behemoth China National Pharmaceutical Group Corporation, seeking to rev up its product accessibility in China. Under the agreement, CSL Behring will initiate a fourth-party logistics operation model covering its imported human albumin products, providing import, logistics and distribution end-to-end services.

CSL Behring, which owns CSL Plasma, one of the world’s largest plasma collection networks, has become a major supplier of human albumin in China, where it has been supplying since 1997. Human albumin is used to treat a variety of diseases, including shock caused by blood loss, burns and infections, and prevention and treatment of hypoproteinemia. The company has already established retailing and distribution partnerships with Sinopharm’s compatriot firms Baheal Pharmaceutical Group and Guangzhou Pharmaceuticals Corporation in December 2018 and February 2019 respectively, as reported by GBI. The latest deal with Sinopharm it expected to ratchet up CSL Behring’s market presence in China, and lay the groundwork for the firm’s sustainable business.


Reference:

Related news
CSL Behring, a wholly owned subsidiary of Australia-based CSL Ltd (ASX:CSL) reportedly signed a strategic memorandum of understanding with China-based Guangzhou Pharmaceuticals Corporation.
China’s Baheal Pharmaceutical Group is set to support CSL Behring in relation to distribution of the latter’s Albuminar (human albumin) product in China, focused on China’s retail terminals.
China-based Humanwell Healthcare Group Co., Ltd, (SH:600079) announced that it has entered into an equity transfer agreement with CSL Behring Asia Pacific Ltd, the wholly owned subsidiary of Australia-headquartered CSL Ltd (ASX:CSL; USOTC:CSLLY), to sell out the remaining 20% stake in Wuhan Zhong Yuan Rui De Biological Products Co., Ltd (Ruide) that CSL did not already own.
Australia-based biotech CSL Ltd (ASX:CSL; USOTC:CSLLY) is moving to increase its direct involvement in the China market.
Shanghai’s Centralized Drug Procurement Management Office issued a circular this month noting that four products would be made available for online procurement due to critical clinical shortages.
Recent news
A Sino-US team of researchers have reported developing a new improved chimeric antigen receptor (CAR) T cell therapy, according to a study published in Nature Medicine.
  • 1556168634038
  • China
  • R&D
China-based Viva Biotech Holdings (1873.HK) announced an initial public offering (IPO) of 345,000,000 shares with price ranging from HKD 3.42 to HKD 4.41 per share.
Switzerland-based ADC Therapeutics and the China-based Adagene announced a discovery partnership and licensing deal focused on the development of next-generation masked antibody drug conjugates (ADCs).
U.S.-based Boston Children's Hospital (BCH) and Sino-US high-end clinics operator and healthcare service provider MORE Health Inc., announced a strategic partnership that will allow Chinese patients to access BCH's physicians for diagnosis and treatment.
China’s National Medical Products Administration (NMPA) released the medical devices awarded market approval during March 2019.
The Brazilian Society of Diabetes (SBD) this week will discuss the benefits of Technosphere insulin, a fast-acting inhalable diabetes treatment.
Brazil's Industry Syndicate of Pharmaceutical Products (SINDUSFARMA) this month presented the results of a study on the viability of the drug inverse logistics system, commissioned to Netherlands-based consulting firm KPMG.
Analytics Snapshot


Actionable intelligence at your fingertips.